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Abstract
Background: Even in absence of obstructive coronary artery disease women with angina pectoris have a poor
prognosis possibly due to coronary microvascular disease. Coronary microvascular disease can be assessed by
transthoracic Doppler echocardiography measuring coronary flow velocity reserve (CFVR) and by positron emission
tomography measuring myocardial blood flow reserve (MBFR). Diffuse myocardial fibrosis can be assessed by
cardiovascular magnetic resonance (CMR) T1 mapping. We hypothesized that coronary microvascular disease is
associated with diffuse myocardial fibrosis.
Methods: Women with angina, a clinically indicated coronary angiogram with <50 % stenosis and no diabetes were
included. CFVR was measured using dipyridamole (0.84 mg/kg) and MBFR using adenosine (0.84 mg/kg). Focal fibrosis
was assessed by 1.5 T CMR late gadolinium enhancement (0.1 mmol/kg) and diffuse myocardial fibrosis by T1 mapping
using a modified Look-Locker pulse sequence measuring T1 and extracellular volume fraction (ECV).
Results: CFVR and CMR were performed in 64 women, mean (SD) age 62.5 (8.3) years. MBFR was performed in a
subgroup of 54 (84 %) of these women. Mean native T1 was 1023 (86) and ECV (%) was 33.7 (3.5); none had focal
fibrosis. Median (IQR) CFVR was 2.3 (1.9; 2.7), 23 (36 %) had CFVR < 2 indicating coronary microvascular disease, and
median MBFR was 2.7 (2.2; 3.0) and 19 (35 %) had a MBFR value below 2.5. No significant correlations were found
between CFVR and ECV or native T1 (R2 = 0.02; p = 0.27 and R2 = 0.004; p = 0.61, respectively). There were also no
correlations between MBFR and ECV or native T1 (R2 = 0.1; p = 0.13 and R2 = 0.004, p = 0.64, respectively). CFVR and
MBFR were correlated to hypertension and heart rate.
Conclusion: In women with angina and no obstructive coronary artery disease we found no association between
measures of coronary microvascular disease and myocardial fibrosis, suggesting that myocardial ischemia induced by
coronary microvascular disease does not elicit myocardial fibrosis in this population. The examined parameters seem to
provide independent information about myocardial and coronary disease.
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Background
More than half of women with angina-like chest pain
referred for clinical coronary angiography (CAG) have
no obstructive coronary artery disease (CAD) [1]. While
previously considered a benign condition, recent studies
have found this condition to be associated with persist-
ent chest pain, reduced quality of life, repeated angiogra-
phies and increased cardiovascular morbidity and
mortality [1, 2]. A possible explanation for this discrep-
ancy between CAG findings and symptoms could be
ischemia caused by coronary microvascular dysfunction
(CMD) which is a strong predictor of cardiovascular
prognosis [3–5]. CMD cannot be visualized by standard
imaging techniques, but by assessing changes in coron-
ary blood flow or vascular resistance. Although endothe-
lium dependent microvascular function can be assessed,
most studies of CMD refer to endothelium independent
function assessed during adenosine or dipyridamole
stress. Prognostic studies have primarily investigated
endothelial-independent measures of CMD by assess-
ment of coronary flow velocity reserve (CFVR) invasively
during the CAG or by transthoracic Doppler echocardi-
ography (TTDE) of the left anterior descending artery
(LAD) [3, 5–8] or by positron emission tomography
(PET) measuring myocardial blood flow reserve (MBFR)
[4, 9, 10]. Other methods include contrast perfusion
echocardiography [11] and invasive thermo-dilution
[12]. TTDE CFVR is the least expensive method - easily
accessible, non-invasive, and free from radiation [6].
Furthermore, the method has shown good repeatability
[13], as well as agreement with invasively measured
CFVR assessed with an intracoronary Doppler wire
[14–17]. PET measured CMD has also shown to agree
with invasive measured CFVR [18].
Myocardial tissue consists of myocytes, blood vessels
and nerves distributed in the extracellular volume
(ECV). Cardiovascular magnetic resonance (CMR) is a
well-validated method to assess expansion of the myo-
cardial ECV, e.g. as seen with fibrosis [19–21]. Fibrosis
of the myocardium is associated with impaired ventricu-
lar function, remodelling and stiffness. Localized focal
myocardial fibrosis can be observed as late gadolinium
enhancement (LGE) after administration of gadolinium
[22], but the more recently developed technique called
T1 mapping is able to quantify diffuse myocardial fibro-
sis [23, 24] and has been validated against histological
myocardial biopsies [19–21].
The iPOWER study (ImProve diagnOsis and treatment
of Women with angina pEctoris and micRovessel
disease) aims to investigate diagnostic techniques and
prognosis of CMD in women with angina-like chest pain
and no obstructive CAD [25]. To date, no study has
evaluated whether these women with possible CMD
have diffuse myocardial fibrosis. The aim of this sub-
study from the iPOWER study was to evaluate the
association between CMD assessed by CFVR and MBFR,
and presence of diffuse myocardial fibrosis assessed by
T1 mapping based on the hypothesis that CMD and
consequent myocardial ischemia induce diffuse myocar-
dial fibrosis.
Methods
Population and baseline assessment
Women with angina-like chest pain, no significant
obstructive CAD assessed by diagnostic invasive CAG
with <50 % stenosis of epicardial vessels, and with a
successful TTDE CFVR examination were randomly
selected for the iPOWER CMR and PET sub-studies [25].
Selection was based on availability of PET and CMR time-
slot, participants’ willingness to participate, and minimiz-
ing time interval between the examinations. Figure 1
displays the defined in- and exclusion criteria in iPOWER.
We included both women referred for stable angina and
women hospitalized suspected of unstable angina, since
the latter may be first manifestation of stable angina.
Further exclusion criteria for the CMR sub-study were
diabetes mellitus or contraindication for CMR. Diabetics
were excluded as the disease is characterized by micro-
vascular disease in order to avoid it being a confounder.
Baseline assessment included clinical and demographic
data from interview, charts and the regional CAG
database. ECG, blood pressure and heart rate were ob-
tained at rest. Blood samples were analyzed for cholesterol
Fig. 1 In- and exclusion criteria in the iPOWER study
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levels (total, low-density lipoprotein [LDL] and high-
density lipoprotein [HDL] cholesterol), and triglycerides.
Framingham risk score was calculated estimating risk for
coronary heart disease over a period of 10 years in women
(1 indicating 100 % risk) [26], as well as HeartScore for
Denmark (a low risk country) estimating the absolute risk
(%) of cardiovascular death within 10 years [27].
Prior to the TTDE, PET and CMR, participants were
instructed to be abstinent for 24 h from caffeine or food
containing significant amount of methylexanthine (coffee,
tea, chocolate, cola and banana) which was confirmed by
the study. Medication containing dipyridamole was paused
for 48 h, long-lasting nitroglycerines, beta-blockers, ACE-
inhibitors, angiotensin-II-antagonist, calcium antagonist,
and diuretics for 24 h and short-lasting nitroglycerines 1 h
before the examination. This was done in order to avoid an
effect on the pharmacological induced hyperemia. Different
vasodilators can be used to induce hyperemia, but adeno-
sine and dipyridamole are regarded as equal to achieve peak
coronary vasodilation [28, 29] and used interchangeably in
clinical practice.
CFVR measurement and analysis
At baseline a TTDE of the LAD during rest and high-dose
dipyridamole stress (0.84 mg/kg) was performed over
6 min to obtain coronary flow velocities (CFV). The
examination was performed using GE Healthcare Vivid E9
cardiovascular ultrasound system (GE Healthcare, Horten,
Norway) with a 2.7 - 8 MHz transducer (GE Vivid 6S
probe). All examinations were performed by the same 3
experienced echocardiographers in the same settings. CFV
was measured by pulsed-wave Doppler as a diastolic
laminar flow towards the transducer. Blood pressure and
heart rate were measured every 3 min during the examin-
ation and after the examination intravenous theophylline
(maximum dose 220 mg) was administered to relieve
potential side effects of dipyridamole. Diastolic peak flow
velocities were analyzed at rest and at peak hyperemia and
CFVR was calculated as the ratio between the two (Fig. 2)
[30, 31]. In our previous validation study with repeated
TTDE CFVR examinations in 10 young, healthy subjects
by the same observer we found an intra class correlation
coefficient of 0.97 (0.92;1.00) and coefficient of variation
(CI) of 7 % for repeat examinations. In a subsample of 50
participants from the iPOWER study, CFVR readings for
two analyzers were highly reproducible with a coefficient
of variation of 2.7 % [25].
MBFR measurement and analysis
PET scans were performed using a Siemens Biograph
hybrid Computed Tomography (CT)/PET 128-slice
scanner (Siemens Healthcare, Knoxville, Tennessee,
USA) [10]. Participants underwent serial image acquisi-
tion at rest and during adenosine infusion in a single
session. For each acquisition, participants received
1.110 MBq (±10 %) Rubidium-82 from a CardioGen-82
strontium-82/Rubidium-82 generator (Bracco Diagnostics
Inc., Princeton, New Jersey, USA). Stress Rubidium-82
Fig. 2 Measurement of coronary flow velocity by transthoracic Doppler echocardiography
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infusion was initiated 2.5 min after initiation of adenosine
infusion. Maximum radiation exposure for the entire
examination was 5.2 mSv.
MBF quantification was performed using syngo MBF
software (Siemens Healthcare, Knoxville, Tennessee,
USA). MBFR was defined as MBF during maximal
hyperaemia divided by MBF at rest. MBFR according to
the coronary arteries (LAD, right coronary artery [RCA],
left circumflex artery [LCX]) was analyzed according to
the AHA 17 segment model [32]. Independent observers
performed all analyses blinded to results of the TTDE
and CMR examination. We did not evaluate the repro-
ducibility of PET MBFR mainly due to ethical reasons as
the method exposes participants to radiation. Other
groups have evaluated reproducibility of Rubidium-82
PET as well as intra- and interobserver reliability with
acceptable agreement [33–35]. We assessed interob-
server variability of the MBFR analysis and found a coef-
ficient of variation (CI) of 6.31 % (5.45;7.18).
CMR
CMR was performed on a Magnetom Avanto 1.5 Tesla
scanner (Siemens, Erlangen, Germany). Prior to the scan
hematocrit was measured for ECV calculation. A 32
channel chest coil combined with back surface coils was
used. Initially scout images were obtained followed by a
short-axis cine covering the heart using retrospective ECG
gated steady-state free precession (SSFP) cine sequences;
field of view 300x300 mm, matrix 192x192, slice thickness
8 mm with 25 number of phases. T1 mapping was per-
formed using the modified look-locker inversion recovery
technique (MOLLI) [36]. Before contrast three short-axis
MOLLI images were obtained (apical, mid-ventricular and
basal). Settings were (5(3)3) referring to 5 acquisition
heart beats, followed by 3 recovery heart beats, then a fur-
ther 3 acquisition heart beats. Field of view 360x360,
matrix 218x256, slice thickness 8 mm, flip angle 35°, TR
(repetition time) 364.70 ms, TE (echotime) 1.12 ms. TI
start was 170 ms with a T1 increment of 80 ms with 2 in-
versions (TI 250). Gadolinium (Gadovist; Bayer Schering
Pharma, Berlin, Germany) (0.1 mmol/kg) was administered
followed by 15 ml saline. Post-contrast MOLLI im-
ages were obtained 10 min after gadolinium adminis-
tration with the same settings as pre-contrast except:
(4(1)3(1), TR 524.80 ms, TE 1.12 ms and 3 inversions
(TI 330) instead of 2.
LGE images were acquired as breath-hold ECG gated,
inversion recovery fast gradient-echo images after the T1
post-contrast session. Initially an inversion time (TI) scout
was performed to find the best inversion time to null the
myocardium. Images were acquired to cover the whole
length of the left ventricle; slice thickness 8 mm, TE
3.38 ms; TR 848.00 ms; flip angle 25°; field of view
340x340, matrix 192x192, GRAPPA acceleration factor 2.
CMR analysis
CMR analysis was performed using commercial available
software CVI42 version 5.1.1 (Circle Cardiovascular
Imaging Inc., Calgary, Canada) blinded to results of the
TTDE and PET examination. All CMR analyses were
performed by the same reader, trained by an expert CMR
physician. The reader and expert performed double read-
ings until the reader could reproduce the expert satisfac-
tory. The coefficients of variation between the reader and
an expert CMR physician were 6.0 % (0.1; 12.0) for LVEF,
2.5 % (0.1; 4.9) for native T1 and 4.4 % (0.1; 8.7) for post-
contrast T1 times. Furthermore intra-observer variability
was 5.9 % (0.1;11.7) for LVEF, 1.7 % (0.1;3.3) for native T1
and 6.3 (0.1; 12.0) for postcontrast T1. Another group
performed repeated MOLLI T1 mapping in 15 healthy
volunteers. Mean difference (SD) for repeated examina-
tions were 14.4 ms (34.7) for native T1 and 4.5 ms (15.4)
for post-contrast T1. Both intra- and interobserver agree-
ment (native T1) were high, mean difference (SD) 2.6 ms
(6.7) and 1.1 ms (8.9), respectively [37].”
Left ventricle mass and volumes were assessed by
manually tracing the epi- and endocardial borders of the
short-axis cine images and stroke volume and left
ventricular ejection fraction calculated (LVEF) [38]. Left
ventricular hypertrophy (LVH) was defined as LVH >
61 g/m2 [39]. Presence of LGE was assessed visually.
T1 times images were analyzed to construct a T1 map.
Endo- and epicardial borders were drawn on all images
divided on 3 slices pre- and post-contrast. The recovery
curve was generated and dicom maps created by the
software. For the T1 map analysis the CVI42 generated
maps were used. Contours of the endo- and epicardial
borders were drawn on the 3 slices using a 20 % endo-
and epicardial offset and 6 segments per slice. For ECV
analysis a region of interest was drawn in the blood pool
avoiding the papillary muscles and the anterior and
inferior insertion of the right ventricle was marked as
reference points.
ECV was calculated by the equation [21]:
ECV ¼ λ  1‐hematocritð Þ;
λ ¼ ΔR1 myocardiumð Þ = ΔR1 blood poolð Þ;
ΔR1 ¼ R1 post‐contrastð Þ – R1 nativeð Þ; R1 ¼ 1=T1
(Fig. 3)
T1 values (native and post-contrast) and ECV was given
globally, for each slice (basal, mid-ventricular and apical)
and according to the coronary arteries (LAD, RCA, LCX)
segments calculated according to the AHA 17-segment
model (true apex not imaged) [32]. If a segment was miss-
ing due to slices being placed with error during the scan,
the artery segment was calculated with a segment less
(maximum 2 missing segments per participant).
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Statistical analyses
Continuous variables with a Gaussian distribution are
expressed as mean ± standard deviation (SD). Median,
interquartile range (IQR) is used for variables with a
non-Gaussian distribution. Count in % is used for
categorical variables. Distribution was assessed visually.
The coefficient of variation between CMR readers was
calculated by dividing SDdif with the mean value and
expressed as a percentage. The 95 % CI for the estimated
coefficient of variation was calculated according to the
equation: (SDdif ± t · SE(SDdif )/mean) · 100 %.
Difference in T1 variables (native, post-contrast and
ECV) according to slice (apical, mid-ventricular and
basal) and artery territory (LAD, RCA and LCX) was
tested by one-way ANOVA.
Correlations were assessed by Pearson’s correlation
coefficient. Logarithm transformed values was used in
case of non-Gaussian distribution of one variable. In
case both variables were skewed Spearman correlation
coefficient was used.
Participants were stratified according to tertiles of
native T1 and ECV and into three groups using pre-
defined CMD defining cut-off points for CFVR and
MBFR to test for differences between groups. Trend-
tests by logistic or linear regression analysis were used
to evaluate the distribution of variables. Dependent vari-
ables with skewed distribution were transformed with
the natural logarithm.
To explore predictors of native T1, ECV, CFVR and
MBFR multivariable linear regression analyses were
performed. All potential explanatory variables with an a
priori defined hypothesis were tested in a prioritized
order as determinants. Outcome variables with a non-
Gaussian distribution were logarithmically transformed
using the natural logarithm.
Statistical analysis was performed using SAS Enter-
prise Guide 7.1, windowed for SAS version 9.4 (SAS
institute Inc., Cary, North Carolina; USA). A two-sided
p-value below 0.05 was considered statistically significant.
Results
Study population
From the iPOWER population with a successful CFVR
measurement 79 participants were recruited for the
CMR study. Two participants could not complete the
CMR scan due to claustrophobia and 13 were scanned
with different software, making ECV calculation impos-
sible and comparisons unreliable. Thus 64 had a
complete CMR for T1 mapping. Mean age (SD) was
62.5 (8.3) years, 70.3 % had stable angina pectoris as
indication for the clinical CAG and 45.3 % had non-
obstructive atherosclerosis. The duration of angina
varied; 38 % had had their angina symptoms under a
year and 34 % for more than 3 years. The overall burden
of cardiovascular risk factors was relatively high
(Table 1). Mean (SD) score in the European Society of
Cardiology (ESC)’s HeartScore was 1.4 (1.2) and in the
Framingham risk score the mean score was 0.093 (0.05).
Median time-interval (IQR) between the TTDE and the
CMR was 112 (59; 237) days.
Of the 64 participants included and in examined in
the iPOWER CMR sub-study 54 (84 %) also had a PET
scan performed measuring MBFR. Mean age was 62
(7.5) years and prevalence of cardiovascular risk factors
was similar to the total study population (Table 1).
Median time-interval between the PET and the CMR
was 97 (37; 225) days.
Measures of diffuse myocardial fibrosis and
cardiovascular risk factors
On a global level mean native T1 was 1023 (86) ms,
post-contrast T1 463 [33] ms and ECV (%) was 33.7
(3.5). Native and post-contrast T1 times increased sig-
nificantly from apex to base and ECV was significantly
higher towards the apical slice. Native T1 times varied
according to coronary artery territory with the highest
value in the RCA territory, where ECV also was highest
Fig. 3 Analysis of T1 mapping CMR images pre- and
postcontrast. Legend: Native T1 (a.) and postcontrast T1 (b.)
map. Regions of interests drawn in the myocardium and in
the blood pool giving T1 values. The extracellular volume
fraction (ECV) was calculated using the T1 times and the
hematocrit using the equation: ECV = λ * (1-hematocrit);
λ = ΔR1 (myocardium) / ΔR1 (blood pool); ΔR1 = R1 (post-contrast) –
R1 (native); R1 = 1/T1
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(Table 2). As expected, native T1 and ECV were associated
(p < 0.001). When stratifying participants in tertiles
according to native T1 and ECV no variables were associ-
ated with both CMR derived measures of fibrosis: low
ECV was associated with more atherosclerosis on the
CAG and low native T1 was associated with more hyper-
tension. Native T1 increased with higher resting heart rate
(Table 3). In multivariable linear regression analysis none
of the examined variables were able to predict ECV and
native T1 (data not shown).
Measures of coronary microvascular dysfunction and
cardiovascular risk factors
Median CFVR was 2.3 (1.9;2.7) and 23 (36 %) had CFVR
below the cut-off of 2. Median MBFR was 2.7 (2.2;3.0)
and 19 (35 %) had a MBFR value below 2.5. The two
measures of CMD were only weakly correlated (p = 0.01,
R2 = 0.132). When stratifying participants according to
CMD defining cut-off points for CFVR and MBFR,
impaired CFVR was associated with smoking and both
CFVR and MBFR were associated with presence of
hypertension and a higher resting heart rate (Table 4),
as also found in multivariable regression analysis (data
not shown).
Table 1 Demographics, Medical History, Biochemistry and CMR






Age, mean (SD) 62.5 (8.3) 62.0 (7.5)
Hypertension, n (%) 38 (59.4) 29 (53.7)
Hyperlipidaemia, n (%) 42 (65.6) 34 (63)
Family history of CAD, n (%) 36 (57.1) 30 (57)
Smoking (current), n (%) 15 (23) 12 (22)
Smoking (previous + current),
n (%)
39 (61) 34 (63)
Pack years (20 cig./day) · year)a,
median (IQR)
27 (7;35) 29 (8;35)
Stable angina pectoris, n (%) 45 (70.3) 39 (72)
Postmenopausal status, n (%) 56 (89) 48 (89)
Comorbidity, n (%) 38 (60) 31 (59)
ESC’s HeartScore (% risk)b,
mean (SD)
1.4 (1.2) 1.3 (1.3)
Framingham risk scorec,
mean (SD)




4.8 (1.0) 4.9 (1.1)
LDL cholesterol (mmol/l),
mean (SD)
2.7 (1.0) 2.8 (1.0)
HDL cholesterol (mmol/l),
mean (SD)
1.6 (0.5) 1.6 (0.5)
Non-HDL cholesterol
(mmol/l), mean (SD)
3.2 (1.0) 3.3 (1.0)
Hematocrit, mean (SD) 40.5 (2.9) 40.7 (2.7)
Clinical Assessment
Body mass index (kg/m2),
median (IQR)
23.9 (21.9;28.3) 23.7 (22.0;27.9)
Body mass index
(kg/m2) > 25, n (%)
26 (41) 22 (40)
Abdominal circumference
(cm), mean (SD)
93.5 (12.4) 93 (12.5)
Systolic blood pressure
(mmHg), mean (SD)
148.1 (25.7) 146.5 (25.8)
Diastolic blood pressure
(mmHg), mean (SD)
85.5 (15.8) 85.6 (16.5)
Heart rate at rest (bpm),
mean (SD)
64.8 (10.3) 64.2 (11.1)
Atherosclerosis at CAG,
n (%)
29 (45) 24 (44)
Cardiac Magnetic Resonance (global values)
Left ventricular ejection
fraction (%), mean (SD)
59.6 (5.9) 59.7 (5.9)
End systolic volume (ml),
mean (SD)
60.6 (17.2) 61.1 (17.4)
End diastolic volume (ml),
mean (SD)
148.5 (27.0) 150.3 (27.8)
Table 1 Demographics, Medical History, Biochemistry and CMR
values for the CFVR population and the part also examined by
PET (MBFR population) (Continued)
Left ventricular mass index
(g/m2), mean (SD)
48.38 (7.6) 49.1 /7.8)
Left ventricular hypertrophy,
n (%)
5 (8) 5 (10)
Cardiac output, mean (SD) 5.7 (1.1) 5.7 (1.2)
Stroke volume, mean (SD) 87.9 (15.3) 89.3 (16.1)
Myocardial mass (diastole),
mean (SD)
87.2 (17.8) 88.2 (18.8)
Myocardial mass (systole),
mean (SD)
92.6 (20.7) 92.9 (21.5)
Medication
Beta Blockers, n (%) 23 (36) 19 (35)
Acetylsalicylic acid, n (%) 35 (54.7) 29 (54)
Statin, n (%) 35 (54.7) 28 (52)
Calcium antagonists, n (%) 17 (27) 13 (25)
Angiotensin conv. enzyme
inhibitor, n (%)
8 (13) 7 (13)
Angiotensin receptor
blockers, n (%)
11 (18) 6 (11)
aOnly including previous and current smokers. bEstimates absolute risk (%) for
cardiovascular death within 10 years. cEstimates risk for coronary heart disease
over a period of 10 years (1 = 100 % risk). CFVR coronary flow velocity reserve,
MBFR myocardial blood flow reserve, IQR interquartile range, SD standard
deviation, CAD coronary artery disease, LDL low-density-lipoprotein, HDL
high-density-lipoprotein, non-HDL non-high-density-lipoprotein cholesterol,
ESC European Society of Cardiology
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Measures of CMD and presence of diffuse myocardial
fibrosis
No significant correlation was found between CFVR and
ECV or native T1, R2 = 0.02; p = 0.27 and R2 = 0.004; p =
0.61 respectively). Similarly, we did not find a correlation
between MBFR and ECV or native T1 (R2 = 0.1; p = 0.13
and R2 = 0.004, p = 0.64, respectively) (Fig. 4). For the 23
participants with CFVR below 2 mean (SD) native T1
was 1046 (123) and ECV 34.5 (4.5). For the 19 women
with MBFR below 2.5 mean (SD) native T1 was 1031
(134) and ECV was 33.3 (3.8). For those women with
TTDE and PET defined CMD there was no difference in
ECV and native T1 compared to women with normal
CFVR and MBFR, p = 0.71 and p = 0.36 respectively.
Furthermore, there was no correlation between MBFR
and ECV or native T1 according to the coronary artery
territory (data not shown).
Discussion
In this study no patient with angina had focal fibrosis
and we found no association between the degree of
CMD assessed by TTDE and PET and the presence of
diffuse myocardial fibrosis measured by CMR, indicating
that myocardial ischemia in this population does not
elicit myocardial fibrosis. This is a new finding, since no
study to date has examined the presence of diffuse
myocardial fibrosis in women with angina pectoris and
no obstructive CAD.
Arnold et al. investigated 50 patients with diabetes
without CAD and 19 matched controls with T1 mapping
[40]. There was no difference in left ventricular volume
measurements between the two groups, but diabetic
patients had significantly shorter post-contrast T1 indi-
cating diffuse myocardial fibrosis. This is interesting
since diabetes is a disease characterized by microvascular
disease. We excluded women with diabetes to avoid this
confounder, but did not find a similar association
between CMD and diffuse myocardial fibrosis. The
prevalence of other cardiovascular risk factors in our
study was relatively high compared to a large Danish
normal population of women of similar age [41] but
comparable to a large Danish study of 2253 women with
angina pectoris and no obstructive CAD [1]. There was
however, no clear association between cardiovascular
risk factors and presence of diffuse myocardial fibrosis,
and HeartScore and Framingham risk scores did not
predict more fibrosis. A MESA (multi-ethnic study of
atherosclerosis) study also examined the association
between T1 mapping values and cardiovascular risk
factors in 1208 subjects (49 % women) and found a poor
correlation between risk scores and presence of diffuse
myocardial fibrosis, particularly in women [42]. These
authors concluded that there was a clinical potential for
T1 mapping to be used in complement with risk scores
to add prognostic value. In another MESA study of 1231
subjects (51 % women) with no focal fibrosis on CMR,
women had significantly higher ECV and native T1
compared to men, indicating more fibrosis, and ECV
was associated with age in women after multivariable
adjustment [43]. This has also been found in another
study of 81 healthy controls [44]. We did not see any
association with age, but more fibrosis was associated
with less hypertension and less atherosclerosis on the
CAG, which should be cautiously interpreted due to the
small study sample size. The latter could also indicate
that the mechanisms causing obstructive CAD, diffuse
myocardial fibrosis and CMD in this population are dis-
tinct. Both native and post-contrast T1 increased signifi-
cantly from apex to base, which has also been seen in
another study in the unaffected part of the myocardium
in patients with myocardial infarction [45].
The cut-off used to define CMD is currently unclear
and should be seen as a continuum [9], but most agree
that values below 2.0 or 2.5 indicate CMD [3, 46, 47]. In
yet unpublished data from the iPOWER study we have,
however demonstrated that MBFR is systematically
higher than CFVR. We found that 36 % had CMD using
a CFVR cut-off value of 2 and 35 % had CMD using a
MBFR cut-off value of 2.5. Only 6 (11 %) had MBFR
below 2. This prevalence is similar to other studies in-
vestigating CMD in this patient population [5, 31, 48, 49].
Impaired CMD was associated with hypertension and
higher resting heart rate which is similar to findings from
other studies [3, 31, 50, 51].
Strengths and limitations
This study used multiple imaging modalities to examine
the association between CMD and presence of diffuse
myocardial fibrosis. The participants were consecutively
included and examined systematically and all had a
Table 2 T1 mapping values according to slice and coronary artery territory
Ventricular Slice Coronary Artery Territory
Basal Mid Apical p-value* LAD RCA LCX p-value*
T1 native (ms) 1043 (38) 1016 (57) 976 (117) <0.0001 992 (48) 1023 (39) 955 (82) <0.0001
T1 postcontrast (ms) 483 (35) 469 (38) 439 (35) <0.0001 464 (37) 459 (64) 477 (40) 0.10
ECV (%) 32.8 (3.3) 33.1 (4.0) 34.6 (5.0) 0.04 32.0 (3.0) 32.1 (3.5) 30.2 (4.0) 0.001
*Differences between groups were tested by one-way ANOVA
ECV extracellular volume, LAD left anterior descending artery, RCA right coronary artery, LCX left circumflex artery
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Table 3 Variables according to measures of diffuse myocardial fibrosis
Extracellular Volume Fraction (%) Native T1 (ms)
<32.3 32.3-34.5 >34.5 p-value* <996 996-1032 T > 1032 p-value*
(n = 22) (n = 21) (n = 21) (n = 22) (n = 21) (n = 21)
T1 native (ms)/ECV (%), mean (SD) 996 (49) 1010 (37) 1065 (129) <0.001** 32.5 (3.2) 33.04 (1.8) 35.6 (4.9) <0.001**
CFVR, median (IQR) 2.2 (1.9;2.6) 2.6 (2.1;2.9) 2.1 (1.7;2.6) 0.27** 2.2 (1.7;2.6) 2.5 (2.0;2.9) 2.2 (1.8;2.6) 0.61**
MBFRa, median (IQR) 2.7 (2.1;2.9) 2.7 (2.2;3.3) 2.7 (2.3;3.0) 0.13** 2.6 (2.0;2.9) 2.8 (2.6;3.2) 2.5 (2.1;2.7) 0.64**
Age (years), mean (SD) 63.5 (7.9) 60.2 (7.8) 63.6 (9.1) 0.31 64.3 (8.2) 61.5 (8.0) 61.5 (8.8) 0.45
BMI (kg/m2), median (IQR) 25 (23;29) 23 (22;26) 23 (22;29) 0.31 24 (22;28) 24 (22;26) 25 (22;29) 0.86
Hypertension, n (%) 15 (68) 12 (57) 11 (52) 0.56 18 (82) 7 (33) 13 (62) 0.01
Smoking (current), n (%) 3 (14) 6 (29) 6 (29) 0.42 4 (18) 3 (14) 8 (38) 0.16
Ever smoked, n (%) 17 (77) 11 (52) 11 (52) 0.17 13 (59) 12 (57) 14 (67) 0.80
Atherosclerosis on CAG, n (%) 16 (73) 6 (29) 7 (33) 0.01 11 (50) 7 (33) 11 (52) 0.41
Non-HDL cholesterol, mean (SD) 3.3 (1) 3.2 (0.9) 3.2 (1.2) 0.84 3.0 (1.1) 3.5 (1.0) 3.3 (0.7) 0.24
Systolic BP (mmHg), mean (SD) 152 (21) 146 (27) 147 (29) 0.71 146 (22) 146 (26) 152 (30) 0.67
Resting HR (bpm), mean (SD) 65 (9.5) 63 (11.8) 67 (9.6) 0.53 65 (11.2) 60 (11.3) 69 (6.5) 0.04
Ejection fraction (%), mean (SD) 61 (5.2) 60 (6.7) 59 (5.9) 0.46 60.9 (4.9) 59.4 (5.7) 58.7 (7.1) 0.48
LV mass index (g/m2), mean (SD) 47.9 (6.5) 48.4 (6.6) 48.8 (9.7) 0.94 46.6 (5.5) 50.3 (8.7) 48.4 (8.3) 0.31
LV hypertrophy, n (%) 1 (5) 1 (5) 3 (14) 0.44 0 (0) 3 (14) 2 (10) 0.84
ESC HeartScore (% risk)b, mean (SD) 1.64 (1.3) 1.00 (1.2) 1.4 (1.1) 0.23 1.5 (1.1) 1.05 (1.3) 1.5 (1.2) 0.37
Framingham risk scorec, mean (SD) 0.1 (0.06) 0.08 (0.04) 0.1 (0.06) 0.35 0.09 (0.05) 0.1 (0.06) 0.09 (0.06) 0.90
Beta blockers, n (%) 9 (41) 9 (43) 5 (24) 0.38 10 (45) 8 (38) 5 (24) 0.34
Acetylsalicylic acid, n (%) 13 (59) 12 (57) 10 (48) 0.73 13 (59) 10 (48) 12 (57) 0.73
Statin, n (%) 15 (68) 13 (62) 7 (33) 0.06 15 (68) 10 (48) 10 (48) 0.30
Calcium antagonists, n (%) 7 (32) 6 (29) 4 (19) 0.61 8 (36) 3 (14) 6 (29) 0.31
ACE inhibitor, n (%) 2 (9) 3 (14) 3 (14) 0.82 5 (23) 1 (5) 2 (10) 0.24
Ang.Rec. Blockers, n (%) 3 (14) 3 (14) 5 (25) 0.65 4 (18) 2 (10) 5 (24) 0.52
*Difference between groups was tested by trend-test: multiple regression for continuous variables & logistic regression for categorical outcome variables. Log transformed values for the outcome variable was used for
the skewed variables. **P-value obtained from Pearson’s correlation coefficient.aParticipants in the 3 MBFR groups were 18, 19 and 20. bEstimates absolute risk (%) for cardiovascular death within 10 years. cEstimates risk
for coronary heart disease over a period of 10 years (1 = 100 % risk)
ECV extracellular volume fraction, CFVR coronary flow velocity reserve, MBFR myocardial blood flow reserve, IQR interquartile range, SD standard deviation, BMI body mass index, CAG coronary angiography, non-HDL,














Table 4 Measures of CMD and cardiovascular risk factors
Coronary Flow Velocity Reserve Myocardial Blood Flow Reserve
<2 2-2.5 >2.5 p-value* <2 2-2.5 >2.5 p-value*
(n = 23) (n = 16) (n = 25) (n = 6) (n = 13) (n = 35)
MBFR/CFVR, median (IQR) 2.2 (2.0;2.7) 2.7 (2.4;2.8) 2.9 (2.5;3.2) 0.01** 2.4 (1.9;2.7) 2.0 (1.7;2.3) 2.6 (2.2;2.9) 0.01**
T1 native (ms), mean (SD) 1046 (123) 1005 (123) 1014 (51) 0.61** 985 (34) 1053 (159) 1013 (55) 0.64**
ECV (%), mean (SD) 34.5 (4.5) 32.6 (2.2) 33.7 (2.9) 0.27** 31.2 (2.7) 34.2 (3.9) 33.6 (2.6) 0.13**
Age (years), mean (SD) 64.0 (10.3) 61.2 (6.4) 61.8 (7.49 0.52 60.2 (7.5) 63.1 (8.6) 61.9 (7.2) 0.74
BMI (kg/m2), median (IQR) 24 (22;27) 23 (21;28) 25 (23;29) 0.42 26 (24;29) 23 (22;24) 25 (22;29) 0.46
Hypertension, n (%) 20 (89) 10 (63) 8 (32) 0.002 5 (83) 10 (77) 14 (40) 0.03
Smoking (current), n (%) 6 (26) 4 (25) 5 (20) 0.87 3 (50) 4 (31) 5 (14) 0.13
Ever smoked, n (%) 14 (61) 14 (88) 11 (44) 0.04 5 (83) 10 (77) 19 (54) 0.22
Atherosclerosis on CAG, n (%) 12 (52) 10 (63) 7 (28) 0.08 5 (83) 5 (39) 14 (40) 0.20
Non-HDL cholesterol, mean (SD) 3.2 (1.0) 3.0 (0.9) 3.5 (1.0) 0.36 3.0 (1.2) 3.5 (0.8) 3.2 (1.1) 0.59
Systolic BP (mmHg), mean (SD) 142 (24) 156 (22) 149 (28) 0.28 151 (18) 141 (30) 148 (26) 0.68
Resting HR (bpm), mean (SD) 68 (10) 68 (12) 60 (9) 0.02 68 (15) 70 (9) 61 (104) 0.05
Ejection fraction (%), mean (SD) 58.6 (6.7) 61.7 (4.2) 59.4 (6.0) 0.30 57.6 (10.0) 58.6 (6.1) 60.6 (4.9) 0.39
LV mass index (g/m2), mean (SD) 45.8 (6.0) 49.7 (8.2) 50.1 (8.2) 0.12 49.4 (2.3) 47.3 (9.8) 49.9 (7.7) 0.61
LV hypertrophy, n (%) 0 (0) 2 (15) 3 (12) 0.96 0 (0) 1 (8) 4 (11) 0.90
ESC HeartScore (% risk)a, mean (SD) 1.3 (1.0) 1.4 (1.2) 1.3 (1.5) 0.91 1.2 (0.8) 1.6 (1.4) 1.2 (1.2) 0.59
Framingham risk scoreb, mean (SD) 0.09 (0.04) 0.1 (0.06) 0.09 (0.06) 0.61 0.1 (0.1) 0.08 (0.03) 0.09 (0.05) 0.67
Beta blockers, n (%) 7 (30) 6 (38) 10 (40) 0.78 1 (17) 5 (38) 13 (37) 0.62
Acetylsalicylic acid, n (%) 14 (61) 7 (44) 14 (56) 0.57 6 (100) 6 (46) 17 (49) 0.10
Statin, n (%) 15 (65) 9 (56) 11 (44) 0.34 6 (100) 5 (38) 17 (48.6) 0.82
Calcium antagonists, n (%) 8 (35) 3 (19) 6 (25) 0.53 3 (50) 3 (23) 7 (21) 0.34
ACE inhibitor, n (%) 2 (9) 4 (25) 2 (8) 0.26 1 (17) 2 (15) 4 (12) 0.92
Ang. Rec. Blockers, n (%) 7 (30) 2 (13) 2 (8) 0.14 0 (0) 2 (15) 4 (12) 0.95
*Difference between groups was tested by trend test: multiple regression for continuous variables & logistic regression for categorical outcome variables. Log transformed values for the outcome variable was used for
the skewed variables. **P-value obtained from Pearson’s correlation coefficient. aEstimates absolute risk (%) for cardiovascular death within 10 years. bEstimates risk for coronary heart disease over a period of 10 years
(1 = 100 % risk)
ECV extracellular volume fraction, CFVR coronary flow velocity reserve, MBFR myocardial blood flow reserve, IQR interquartile range, SD standard deviation, BMI body mass index, CAG coronary angiography, non-HDL














clinical invasive CAG ruling out obstructive CAD. The
use of Doppler echocardiography measuring CFVR is a
difficult method that requires training and in un-
experienced hands this would be a limitation. We
assessed repeatability of TTDE CFVR in our group and
found an intra class correlation coefficient of 0.97
(0.92;1.00) and coefficient of variation (CI) of 7 % [3, 10]
for repeat examinations. The study population was
rather small and we cannot rule out that the variation in
T1 values and CMD is too small to catch a possible
association. However, the study size is fair for an
imaging study and the distribution of cardiovascular risk
factors was high, indicating that we have included
women at risk. Also, the duration of time between the
different examinations was relatively large. However,
very few subjects had changes in their medication and
cardiac symptoms in-between examinations and the
level of pharmacological treatment was the same
throughout the study. None of the participants went
through further clinical evaluation during the study
period. This was addressed by having all participants
filling out a questionnaire regarding their cardiac
symptoms and clinical evaluation, as well as checking
the electronic medical chart for new prescriptions
during the time interval. Women with no angina but
only dyspnea as key symptom leading to a clinical
CAG were not included in iPOWER which could
potentially induce sampling bias. However, angina is
the most common symptom of ischemia and women
with only dyspnea and no obstructive CAD are likely
to have another explanation to their symptoms than
myocardial ischemia.
Conclusion
In women with angina pectoris and no obstructive CAD
we found no association between CMD defined by
impaired CFVR or MBFR and diffuse or focal myocardial
fibrosis measured by CMR derived T1 or ECV. This
indicates that these methods and measurements may
provide independent information about different aspects
of myocardial and coronary disease in this population.
Perspectives
That diffuse myocardial fibrosis is not a consequence of
CMD in women with angina and no obstructive CAD
adds knowledge to the field regarding mechanisms caus-
ing angina in these subjects. Such women represent a
large patient group in increased risk of cardiovascular
events for whom there is currently no effective treat-
ment. Future prospective large-scale studies are required
to define the mechanisms causing the diverse symptoms
in this population.
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